Analysis of animal-to-human translation shows that only 5% of animal-tested therapeutic interventions obtain regulatory approval for human applications
PLOS Biology · 13.06.2024 · 22 (6) · e3002667
DOI: 10.1371/journal.pbio.3002667 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Biology, online erschienen am 13.06.2024. Verfasst von Benjamin V Ineichen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Reproducible Science, University of Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Translational Research, Biomedical. Die Arbeit wurde bisher 107-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swiss National Science Foundation, Digital Entrepreneur Fellowship, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung.
Abstract (Originalsprache)
There is an ongoing debate about the value of animal experiments to inform medical practice, yet there are limited data on how well therapies developed in animal studies translate to humans. We aimed to assess 2 measures of translation across various biomedical fields: (1) The proportion of therapies which transition from animal studies to human application, including involved timeframes; and (2) the consistency between animal and human study results. Thus, we conducted an umbrella review, including English systematic reviews that evaluated the translation of therapies from animals to humans. Medline, Embase, and Web of Science Core Collection were searched from inception until August 1, 2023. We assessed the proportion of therapeutic interventions advancing to any human study, a randomized controlled trial (RCT), and regulatory approval. We meta-analyzed the concordance between animal and human studies. The risk of bias was probed using a 10-item checklist for systematic reviews. We included 122 articles, describing 54 distinct human diseases and 367 therapeutic interventions. Neurological diseases were the focus of 32% of reviews. The overall proportion of therapies progressing from animal studies was 50% to human studies, 40% to RCTs, and 5% to regulatory approval. Notably, our meta-analysis showed an 86% concordance between positive results in animal and clinical studies. The median transition times from animal studies were 5, 7, and 10 years to reach any human study, an RCT, and regulatory approval, respectively. We conclude that, contrary to widespread assertions, the rate of successful animal-to-human translation may be higher than previously reported. Nonetheless, the low rate of final approval indicates potential deficiencies in the design of both animal studies and early clinical trials. To ameliorate the efficacy of translating therapies from bench to bedside, we advocate for enhanced study design robustness and the reinforcement of generalizability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Centre for Reproducible Science, University of Zurich, Zurich, Switzerland.
- Clinical Neuroscience Center, University of Zurich, Zurich, Switzerland.
- Department of Mathematics, University of Zurich, Zurich, Switzerland.
- Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, United Kingdom.
ORCID-Profile: Benjamin V Ineichen
Förderung
- Swiss National Science Foundation
- Digital Entrepreneur Fellowship
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- Universität Zürich
- Universities Federation for Animal Welfare
Zitieren
APA
Ineichen, B. V., Furrer, E., Grüninger, S. L., Zürrer, W. E., & Macleod, M. R. (2024). Analysis of animal-to-human translation shows that only 5% of animal-tested therapeutic interventions obtain regulatory approval for human applications. PLOS Biology, 22(6), e3002667. https://doi.org/10.1371/journal.pbio.3002667
Vancouver
Ineichen BV, Furrer E, Grüninger SL, Zürrer WE, Macleod MR. Analysis of animal-to-human translation shows that only 5% of animal-tested therapeutic interventions obtain regulatory approval for human applications. PLOS Biology. 2024;22(6):e3002667. doi:10.1371/journal.pbio.3002667
BibTeX
@article{Ineichen2024,
author = {Ineichen, Benjamin V and Furrer, Eva and Grüninger, Servan L and Zürrer, Wolfgang E and Macleod, Malcolm R},
title = {Analysis of animal-to-human translation shows that only 5% of animal-tested therapeutic interventions obtain regulatory approval for human applications},
journal = {PLOS Biology},
year = {2024},
volume = {22},
number = {6},
pages = {e3002667},
doi = {10.1371/journal.pbio.3002667}
}
EUVIMED